Rigel Pharmaceuticals, Inc. (RIGL)

Rigel Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	294.28	179.28	116.88	120.24	149.24
Revenue Growth (YoY)	64.15%	53.38%	-2.79%	-19.43%	37.39%
Cost of Revenue	19.62	18.65	7.11	1.75	1.08
Gross Profit	274.66	160.63	109.77	118.49	148.15
Selling, General & Admin	115.9	113.06	105.74	112.45	91.89
Research & Development	33.3	23.38	24.52	60.27	65.24
Other Operating Expenses	-	-	-	1.32	3.52
Total Operating Expenses	149.2	136.44	130.26	174.04	160.65
Operating Income	125.47	24.19	-20.49	-55.55	-12.5
Interest Income	3.68	2.09	2.27	0.68	0.05
Interest Expense	-7.32	-7.92	-6.87	-3.71	-4.86
Total Non-Operating Income (Expense)	-3.64	-5.83	-4.6	-3.02	-4.81
Pretax Income	121.83	18.37	-25.09	-58.57	-17.31
Provision for Income Taxes	-245.2	0.88	-	-	0.61
Net Income	367.02	17.49	-25.09	-58.57	-17.91
Net Income to Common	367.02	17.49	-25.09	-58.57	-17.91
Net Income Growth	1999.08%	-	-	-	-
Shares Outstanding (Basic)	18	18	17	17	17
Shares Outstanding (Diluted)	19	18	17	17	17
Shares Change (YoY)	6.52%	1.64%	2.07%	-0.00%	1.03%
EPS (Basic)	20.40	0.99	-1.44	-3.44	-1.10
EPS (Diluted)	19.48	0.99	-1.44	-3.44	-1.10
EPS Growth	1867.68%	-	-	-	-
Free Cash Flow	75.66	31.44	-5.74	-74.21	5.25
Free Cash Flow Growth	140.67%	-	-	-	-
Free Cash Flow Per Share	4.02	1.78	-0.33	-4.35	0.31
Gross Margin	93.33%	89.60%	93.92%	98.55%	99.27%
Operating Margin	42.63%	13.49%	-17.53%	-46.20%	-8.37%
Profit Margin	124.72%	9.75%	-21.47%	-48.71%	-12.00%
FCF Margin	25.71%	17.53%	-4.91%	-61.72%	3.52%
EBITDA	127.88	26.42	-19.25	-54.55	-11.33
EBITDA Margin	43.46%	14.74%	-16.47%	-45.37%	-7.59%
EBIT	125.47	24.19	-20.49	-55.55	-12.5
EBIT Margin	42.63%	13.49%	-17.53%	-46.20%	-8.37%
Effective Tax Rate	-201.27%	4.80%	0.00%	0.00%	-3.50%

Updated Mar 3, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q